A multicenter study of new anticancer agent for patients with advanced hepatocellular carcinoma : efficacy and safety

A multicenter study of new anticancer agent for patients with advanced hepatocellular carcinoma : efficacy and safety - A multicenter study of new anticancer agent for patients with advanced hepatocellular carcinoma : efficacy and safety

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002394

Enrollment

2000

Registered

2009-09-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hapatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hepatocellular carcionoma confirmed by dynamic CT or dynamic MRI, or histologically confirmed hepatocellular carcinoma 2) Unresectable advanced hepatocellular carcinoma treated by new anticancer agent 3) Written informed consents

Exclusion criteria

Exclusion criteria: 1) Contraindication of new anticancer agent 2) The investigator consider not suitable for the study

Design outcomes

Primary

Measure	Time frame
Safety of new anti-cancer agents : Incidence of adverse event	—

Secondary

Measure	Time frame
Efficacy of new anti-cancer agents : Overall survival, progression-free survival, time to disease progression, overall response rate	—

Countries

Japan

Contacts

Public ContactTatsuya Yamashita

Kanazawa University Hospital Department of Gastrenterology

ytatsuya@m-kanazawa.jp076-265-2861

Outcome results